cvPipeline Launches Drug-Eluting Stent Online Database Service Providing Daily Updating of Competitive R&D DES Landscape

SAN FRANCISCO--April 19, 2006—MarketMonitors, Inc. (MMI), a provider of online business intelligence and analytic databases, has launched the Drug-Eluting Stent sector of cvPipeline™. This online resource is the first to provide business executives, investors, and industry analysts with a unified, daily updated view of the R&D landscape and competitive status for new drug-eluting stents (DES) in development. Subscribers can quickly and easily track R&D developments, understand the evolving dynamics of this rapidly changing market, and learn about clinical trials underway worldwide. 

The new DES sector of cvPipeline includes:

-- 90-plus profiles of DES R&D programs in development

-- Nearly 40 profiles of DES products targeting complex lesions or patient subsets, including diabetes, acute myocardial infarction, bifurcation lesions, CTOs, left main disease, and more

--35 private DES companies profiled

--25 profiles of coatings and polymers for use in DES and the 20-plus companies behind them

--Over 200 clinical trials detailed and discussed, with information on protocols, endpoints, data results, and investigators; preclinical data also presented

-- Reports on data and investigator insights presented at a variety of industry and scientific meetings, including CRT, ACC, the DES Revolution, AHA, TCT, EuroPCR, and Medtech Insight’s “In3” and “In Circulation” meetings, among others.

Other types of information included in cvPipeline’s DES sector are milestone calendars, peer-reviewed journal manuscripts, startup company funding history, U.S. patents and applications, technology differentiators, and more.

"Given the rapid pace of change in the R&D landscape for DES, this is a crucial time for investors and industry to gain access to a sophisticated business intelligence tool focused on this exciting market," said Hollis Call, CEO of MarketMonitors. "cvPipeline’s one-stop, up-to-date service helps answer critical questions, such as: Who is investing in DES and which types of products are getting funded? What are the newest DES entrants and what is their U.S. IP portfolio? What differentiates earlier-stage DES products, and who is ahead in the race to market? How are DES products in clinicals performing and how do trial protocols and results compare?"

Methodology

cvPipeline’s DES sector was developed by experienced medtech journalists through the systemic, methodical synthesis of publicly available information, supplemented by exclusive interviews with company executives, investigators, and top clinicians in the field.

Sources include:

--Exclusive interviews

--Patents and applications

--Presentations, posters, and abstracts at scientific meetings and conferences

--Manuscripts published in peer-reviewed scientific literature

--Press releases

--SEC filings

--Company presentations and analyst calls

--FDA advisory panel meetings

cvPipeline Service Design

To help customers manage and analyze the enormous amount of available information, cvPipeline has powerful tools and features that make it easy for customers to drill down into key details, or roll up to summary views. Users of cvPipeline, for example, can seamlessly navigate from a summary view of a selected company’s product portfolio to the details of a clinical study. Multiple databases make it easy to locate information, whether about a company or a product. Separate databases that provide a unique focus on people, patents, and clinical trials will be available soon. An email alert service is also available.

About cvPipeline

As the cardiovascular technology market authority, cvPipeline helps industry executives and investors track, analyze, and understand R&D products for the cardiovascular technology market.

The following sectors are currently available on cvPipeline:

--Atrial fibrillation—65 R&D programs, 35 companies

--Heart failure—90+ R&D programs, nearly 55 companies

--Heart valves—75 R&D programs, nearly 35 companies

--Regenerative medicine—60+ R&D programs, 50+ companies

--Drug-eluting stents—120 R&D programs, 60+ companies

cvPipeline’s services include daily access to in-depth profiles of new products in development, including milestone calendars and status comparisons, clinical trial data, intellectual property; information on management, scientific advisors, and funding for startups; and the ability to drill down to analyze details or roll up across products to gain summary views of the competitive landscape.

Pricing and Availability

The DES sector is now available for purchase, along with cvPipeline’s sectors for atrial fibrillation, heart failure, heart valves, and regenerative medicine. Various subscription packages and services are available. For more information, visit http://www.cvpipeline.com or email info@marketmonitors.com.

About MarketMonitors

MarketMonitors, Inc. (MMI) (www.marketmonitors.com) provides online business intelligence and analytic databases to the medical device and biologics industries. In addition to cvPipeline, the company has developed other online services, including customized access to large-volume medical claims data for market analysis and sales force support. One of MMI’s investors is Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

CONTACT: Hollis Call, MarketMonitors President and CEO: 650.331.0001; hcall@marketmonitors.com; www.marketmonitors.com